Vojnosanitetski pregled 2022 Volume 79, Issue 2, Pages: 204-205
https://doi.org/10.2298/VSP2202204M
Full text (
209 KB)
Cited by
Clinical alert: “Non-clonal” myelodysplastic syndrome
Marisavljević Dragomir (University of Belgrade, Faculty of Medicine, Belgrade, Serbia)
Bogdanović Andrija 
(University of Belgrade, Faculty of Medicine, Belgrade, Serbia)
Show references
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127(20):2391-405.
NCCN Guidelines Version 1.2020-August 27, 2019. Myelodysplastic Syndromes. http://medi-guide.meditool.cn/ymtpdf/A1721A1C-DA35-3F68-122A-3429A1F100BF.pdf
Marisavljević D, Rolović Z, Sefer D, Basara N, Ilić D, Bosković D, Colović M. Biological and clinical significance of clonogenic assays in patients with myelodysplastic syndromes. Med Oncol 2002; 19(4): 249-59.
Kohlmann A, Bacher U, Schnittger S, Haferlach T. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing. Leuk Lymphoma 2014; 55: 1725-34.
Font P, Loscertales J, Benavente C, Bermejo A, Callejas M, Garcia-Alonso L, et al. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. Ann Hematol 2013; 92: 19-24.